{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:28:12Z","timestamp":1790807292191,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Industrial Ties Research Subprogram, Louisiana Board of Regents"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R41 HL142403"],"award-info":[{"award-number":["R41 HL142403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Peripheral artery disease (PAD) is a systemic vascular disease of the legs that results in a blockage of blood flow from the heart to the lower extremities. Now one of the most common causes of mortality in the U.S., the first line of therapy for PAD is to mechanically open the blockages using balloon angioplasty. Coating the balloons with antiproliferative agents can potentially reduce vessel re-narrowing, or restenosis after surgical intervention, but current drug-coated balloons releasing chemotherapy agents like paclitaxel have in some cases shown increased mortality long-term. Our aim was to design a novel drug-coated balloon using a polymeric nanodelivery system for a sustained release of polyphenols that reduce restenosis but with reduced toxicity compared to chemotherapy agents. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles with entrapped quercetin, a dimethoxy quercetin (rhamnazin), as well as quercetin covalently attached to PLGA, were developed. Balloon catheters were coated with polymeric nanoparticles using an ultrasonic method, and nanoparticle characteristics, drug loading, coating uniformity and drug release were determined. The adhesion of nanoparticles to vascular smooth muscle cells and the antiproliferative effect of nano-delivered polyphenols were also assessed. Of the nanoparticle systems tested, those with covalently attached quercetin provided the most sustained release over a 6-day period. Although these particles adhered to cells to a smaller extent compared to other nanoparticle formulations, their attachment was resistant to washing. These particles also exhibited the greatest anti-proliferative effect. In addition, their attachment was not altered when the cells were grown in calcifying conditions, and in PAD tissue calcification is typically a condition that impedes drug delivery. Moreover, the ultrasonic coating method generated a uniform balloon coating. The polymeric nanoparticle system with covalently attached quercetin developed herein is thus proposed as a promising platform to reduce restenosis post-angioplasty.<\/jats:p>","DOI":"10.1371\/journal.pone.0268307","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T13:34:40Z","timestamp":1661348080000},"page":"e0268307","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nanoparticle coatings for controlled release of quercetin from an angioplasty balloon"],"prefix":"10.1371","volume":"17","author":[{"given":"Ioana","family":"Craciun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-9277","authenticated-orcid":true,"given":"Carlos E.","family":"Astete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-5112","authenticated-orcid":true,"given":"Dorin","family":"Boldor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merilyn H.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake D.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina M.","family":"Sabliov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4763-0603","authenticated-orcid":true,"given":"Tammy R.","family":"Dugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"8","key":"pone.0268307.ref001","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"P Song","year":"2019","journal-title":"The Lancet Global Health"},{"issue":"9","key":"pone.0268307.ref002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jacc.2014.12.036","article-title":"Evaluation and treatment of patients with lower extremity peripheral artery disease: Consensus definitions from peripheral academic research consortium (PARC)","volume":"65","author":"MR Patel","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"pone.0268307.ref003","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.avsg.2010.03.015","article-title":"Clinical Outcomes and Medical Care Costs Among Medicare Beneficiaries Receiving Therapy for Peripheral Arterial Disease","volume":"24","author":"MR Jaff","year":"2010","journal-title":"Annals of Vascular Surgery"},{"issue":"19","key":"pone.0268307.ref004","first-page":"2020","article-title":"This article is copublished in Circulation, Catheterization and Cardiovascular Interventions, the Journal of Vascular Surgery, and Vascular Medicine","volume":"58","author":"JA Beckman","year":"2011","journal-title":"Jac"},{"issue":"3","key":"pone.0268307.ref005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","article-title":"Peripheral artery disease: epidemiology and global perspectives","volume":"14","author":"FGR Fowkes","year":"2017","journal-title":"Nature Reviews Cardiology"},{"key":"pone.0268307.ref006","first-page":"1","article-title":"Peripheral arterial disease","volume":"358","author":"CJ Marrocco","year":"2010","journal-title":"High Risk Diabetic Foot: Treatment and Prevention"},{"key":"pone.0268307.ref007","first-page":"3","article-title":"Patient and lesion characteristics in late\/very late stent thrombosis with everolimus-eluting stents from real-world adverse event reporting","author":"A Konishi","year":"2019","journal-title":"Journal of Cardiology"},{"issue":"22","key":"pone.0268307.ref008","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","article-title":"ESC Guidelines on the diagnosis and treatment of peripheral artery diseases","volume":"32","author":"M Tendera","year":"2011","journal-title":"European Heart Journal"},{"key":"pone.0268307.ref009","first-page":"726","article-title":"2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease","volume":"135","author":"C Barrett","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"pone.0268307.ref010","first-page":"81","article-title":"Inter-society consensus for the management of peripheral arterial disease","volume":"26","author":"L Norgren","year":"2007","journal-title":"International angiology: a journal of the International Union of Angiology"},{"issue":"2","key":"pone.0268307.ref011","first-page":"318","article-title":"Endovascular therapy for peripheral arterial disease","volume":"69","author":"K Urasawa","year":"2011","journal-title":"Nippon rinsho Japanese journal of clinical medicine"},{"key":"pone.0268307.ref012","unstructured":"Analysis AE-b. Stenting for peripheral artery disease of the lower extremities: An evidence-based analysis2010. 1\u201388 p."},{"issue":"9","key":"pone.0268307.ref013","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCRESAHA.116.303503","article-title":"Endovascular Intervention for Peripheral Artery Disease","volume":"116","author":"AK Thukkani","year":"2015","journal-title":"Circulation Research"},{"issue":"18","key":"pone.0268307.ref014","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/CIRCULATIONAHA.107.715433","article-title":"Overview of new technologies for lower extremity revascularization","volume":"116","author":"JH Rogers","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"pone.0268307.ref015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/jbm.b.34157","article-title":"Nanoentrapped polyphenol coating for sustained drug release from a balloon catheter","volume":"107","author":"TR Dugas","year":"2019","journal-title":"Journal of Biomedical Materials Research\u2014Part B Applied Biomaterials"},{"issue":"6","key":"pone.0268307.ref016","first-page":"558","article-title":"Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon","volume":"12","author":"RM Ali","year":"2019","journal-title":"JACC: Cardiovascular Interventions"},{"issue":"4","key":"pone.0268307.ref017","first-page":"508","article-title":"In-stent restenosis management: The best is yet to come","volume":"58","author":"JC Van Den Berg","year":"2017","journal-title":"Journal of Cardiovascular Surgery"},{"issue":"3","key":"pone.0268307.ref018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1479164111430336","article-title":"Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents","volume":"9","author":"SN Goyal","year":"2012","journal-title":"Diabetes and Vascular Disease Research"},{"issue":"13","key":"pone.0268307.ref019","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.107.735985","article-title":"Inhibition of restenosis in femoropopliteal arteries. Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial","volume":"118","author":"M Werk","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"pone.0268307.ref020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized Trial","volume":"131","author":"G Tepe","year":"2015","journal-title":"Circulation"},{"issue":"7","key":"pone.0268307.ref021","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa0706356","article-title":"Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg","volume":"358","author":"G Tepe","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"pone.0268307.ref022","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehv204","article-title":"Drug-coated balloon treatment for lower extremity vascular disease intervention: An international positioning document","volume":"37","author":"B Cortese","year":"2016","journal-title":"European Heart Journal"},{"key":"pone.0268307.ref023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-92600-1_6","article-title":"Technical Insights on Drug-Coated Balloons II","author":"M Doshi","year":"2019","journal-title":"Drug-Coated Balloons"},{"issue":"5","key":"pone.0268307.ref024","first-page":"597","article-title":"Paclitaxel eluting balloon: From bench to bedside","volume":"57","author":"R Marzullo","year":"2009","journal-title":"Minerva Cardioangiologica"},{"issue":"9444","key":"pone.0268307.ref025","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"EP McFadden","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"pone.0268307.ref026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/hc3001.092037","article-title":"Pathological analysis of local delivery of paclitaxel via a polymer-coated stent","volume":"104","author":"A Farb","year":"2001","journal-title":"Circulation"},{"key":"pone.0268307.ref027","first-page":"13","volume":"57","author":"Fda","year":"2019","journal-title":"August 7, 2019 UPDATE: Treatment of Peripheral Arterial Disease with Paclitaxel-Coated Balloons and Paclitaxel-Eluting Stents Potentially Associated with Increased Mortality"},{"issue":"6","key":"pone.0268307.ref028","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/ajpheart.00892.2013","article-title":"Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-\u03b1-dependent pathway","volume":"306","author":"A Yurdagul","year":"2014","journal-title":"American Journal of Physiology\u2014Heart and Circulatory Physiology"},{"issue":"9","key":"pone.0268307.ref029","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/ATVBAHA.119.312864","article-title":"Pathologic disparities between peripheral artery disease and coronary artery disease","volume":"40","author":"N Narula","year":"2020","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"issue":"1","key":"pone.0268307.ref030","doi-asserted-by":"crossref","first-page":"RA1","DOI":"10.12659\/MSM.882181","article-title":"The mechanism of vascular calcification\u2013a systematic review","volume":"18","author":"W Karwowski","year":"2012","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"},{"issue":"1","key":"pone.0268307.ref031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.CIR.86.1.64","article-title":"Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound","volume":"86","author":"PJ Fitzgerald","year":"1992","journal-title":"Circulation"},{"issue":"4","key":"pone.0268307.ref032","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00270-014-0904-3","article-title":"Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease","volume":"37","author":"F Fanelli","year":"2014","journal-title":"Cardiovascular and interventional radiology"},{"issue":"5","key":"pone.0268307.ref033","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ahj.2003.10.047","article-title":"Vascular smooth muscle cells and calcification in atherosclerosis","volume":"147","author":"A Trion","year":"2004","journal-title":"American heart journal"},{"issue":"11","key":"pone.0268307.ref034","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/bioinformatics\/btp184","article-title":"Globally optimal stitching of tiled 3D microscopic image acquisitions","volume":"25","author":"S Preibisch","year":"2009","journal-title":"Bioinformatics"},{"issue":"34","key":"pone.0268307.ref035","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1016\/j.biomaterials.2005.04.060","article-title":"Surface charge and the effect of excess calcium ions on the hydroxyapatite surface","volume":"26","author":"IS Harding","year":"2005","journal-title":"Biomaterials"},{"key":"pone.0268307.ref036","doi-asserted-by":"crossref","unstructured":"Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. 2013.","DOI":"10.1038\/nrcardio.2013.165"},{"issue":"2","key":"pone.0268307.ref037","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/SLA.0000000000001676","article-title":"Endovascular Versus Open Revascularization for Peripheral Arterial Disease","volume":"265","author":"JT Wiseman","year":"2017","journal-title":"Ann Surg"},{"key":"pone.0268307.ref038","article-title":"When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease?","author":"AF AbuRahma","year":"2018","journal-title":"Annals of Vascular Diseases"},{"key":"pone.0268307.ref039","unstructured":"Omeh DJ, Shlofmitz E. Restenosis. StatPearls [Internet]. 2020."},{"issue":"3","key":"pone.0268307.ref040","doi-asserted-by":"crossref","first-page":"H902","DOI":"10.1152\/ajpheart.00130.2003","article-title":"Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis","volume":"286","author":"A Curcio","year":"2004","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"3","key":"pone.0268307.ref041","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/01.CIR.88.3.1310","article-title":"Defining coronary restenosis. Newer clinical and angiographic paradigms","volume":"88","author":"RE Kuntz","year":"1993","journal-title":"Circulation"},{"issue":"17","key":"pone.0268307.ref042","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1161\/01.CIR.0000163587.36485.A7","article-title":"Molecular basis of restenosis and drug-eluting stents","volume":"111","author":"MA Costa","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"pone.0268307.ref043","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ccd.25895","article-title":"A single stent strategy in patients with lifestyle limiting claudication: 3\u2010year results from the Durability II trial","volume":"86","author":"KJ Rocha\u2010Singh","year":"2015","journal-title":"Catheterization and Cardiovascular Interventions"},{"issue":"2","key":"pone.0268307.ref044","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jacc.2004.11.026","article-title":"Prevalence and clinical impact of stent fractures after femoropopliteal stenting","volume":"45","author":"D Scheinert","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"pone.0268307.ref045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2012.01.008","article-title":"Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization","volume":"159","author":"JJ Kleinedler","year":"2012","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"pone.0268307.ref046","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jbm.b.31894","article-title":"Synergistic effect of resveratrol and quercetin released from drug\u2010eluting polymer coatings for endovascular devices","volume":"99","author":"JJ Kleinedler","year":"2011","journal-title":"Journal of Biomedical Materials Research Part B: Applied Biomaterials"},{"key":"pone.0268307.ref047","doi-asserted-by":"crossref","DOI":"10.1017\/UPO9781922064004.008","article-title":"7\u2022 Biology of Restenosis and Targets for Intervention","volume":"115","author":"RD Kenagy","year":"2011","journal-title":"Mechanisms of Vascular"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T13:35:55Z","timestamp":1661348155000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268307"}},"subtitle":[],"editor":[{"given":"Wenguo","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268307","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.28.489902","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}